Price $85.51 |
Market Cap
205.15B
|
Sector Health Care |
Div. Growth
8.40%
|
|
P/E
24.9
|
P/B
7.44
|
P/S
4.75
|
Dividend %
2.80%
|
|
P/CF
59.1
|
P/FCF
69.9
|
Op. Cash Flow
11.1M
|
FCF
1.1
|
|
Op. Margin
24.40%
|
Net Margin
19.50%
|
ROE
28.20%
|
ROI
11.20%
|
|
ROA
10.00%
|
EPS Growth
451.70%
|
Current Ratio
1.2
|
Debt/Equity
74.20%
|
| Company | Price | P/E | Div. Yield | Market Cap ($Mil) | Rating |
|---|---|---|---|---|---|
| R1 RCM Inc (RCM) | $12.22 | - | - | 1.32B | Strong Buy |
| Harvard Bioscience, Inc. (HBIO) | $2.04 | - | - | 87.4M | Strong Buy |
| Fulgent Genetics Inc (FLGT) | $5.40 | - | - | 106.5M | Strong Buy |
| Esperion Therapeutics Inc (ESPR) | $48.64 | - | - | 1.31B | Strong Buy |
| TearLab Corp (TEAR) | $0.08 | - | - | 1.1M | Strong Buy |
Please note that all recommendations are based on our model's results and do not represent our personal opinion. The stock Rating process is purely mechanical.
All analysis relies on publicly available financial information. Learn More
